Conservative Balance Sheet / Low LeverageLinc’s near-zero debt and a large equity base (~4.4bn) materially reduce financial risk, allowing the firm to support portfolio companies and absorb valuation shocks. This capital flexibility sustains long-term ability to make follow-on investments without reliance on external borrowing.

Focused Life-sciences Investment Model With Active SupportA focused mandate in medtech, biotech and pharmaceuticals with active portfolio support leverages sector expertise and network effects, increasing likelihood of value creation across holdings. This structural specialization aligns with long-term secular growth in life sciences and enhances deal sourcing and operational support capabilities.

Recent Revenue Rebound And Strong Gross MarginThe sharp 2025 revenue rebound and high gross margin indicate the portfolio delivered realizations or operating improvements, boosting top-line monetization potential. Sustained ability to convert asset value into revenue/gross profit would support cash generation and reduce reliance on one-off exits over the medium term.

Bears Say

Extreme Earnings Volatility And Large 2025 LossLinc’s earnings swing from large profits to very large losses undermines predictability of returns and complicates capital allocation. Large valuation write-downs or impairments materially affect equity and hinder planning for distributions or reinvestment, posing persistent execution and performance risk for investors.

Uneven Cash Generation; FCF Fell To Zero In 2025Inconsistent operating cash flow and a reduction of free cash flow to zero in 2025 constrain financial flexibility to fund follow-on investments, cover operating costs, or return capital. Persistent cash volatility increases the likelihood of asset sales at inopportune times and reduces strategic optionality.

Revenue And Cash Depend On Portfolio Exits, Not Recurring OperationsThe firm’s reliance on portfolio value appreciation and exit timing creates structural income volatility and illiquidity risk. Without recurring fee or operating revenue, cash flows and distributions depend on market conditions and private-company outcomes, limiting predictable long-term revenue and dividend capacity.

LINC FAQ

What was Linc AB’s price range in the past 12 months?

Linc AB lowest stock price was kr58.90 and its highest was kr83.60 in the past 12 months.

What is Linc AB’s market cap?

Linc AB’s market cap is kr3.72B.

When is Linc AB’s upcoming earnings report date?

Linc AB’s upcoming earnings report date is Apr 28, 2026 which is in 68 days.

How were Linc AB’s earnings last quarter?

Linc AB released its earnings results on Jan 22, 2026. The company reported -kr1.868 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.868.

Is Linc AB overvalued?

According to Wall Street analysts Linc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Linc AB pay dividends?

Linc AB does not currently pay dividends.

What is Linc AB’s EPS estimate?

Linc AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Linc AB have?

Linc AB has 57,910,446 shares outstanding.

What happened to Linc AB’s price movement after its last earnings report?

Linc AB reported an EPS of -kr1.868 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.

Which hedge fund is a major shareholder of Linc AB?

Currently, no hedge funds are holding shares in SE:LINC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Linc AB

Linc AB is a private equity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.private eequity and venture capital firm, specializing in early, mid and late venture investments in pharmaceutical, life-science and med-tech companies, respectively. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million to SEK 250 million, the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB is based in Stockholm, Sweden.